Binosto® is an effervescent tablet that forms a buffered alendronate (tablets who form an alendronate buffered) solution at a pH of 4.8-5.4. Binosto® is indicated for the treatment of osteoporosis in postmenopausal women and in men
- Weekly tablets 70 mg
- Box of 4 and 12
- Shelf life : 4 years
Binosto® is indicated for the treatment of osteoporosis in postmenopausal women and in men. The recommended dosage is an effervescent tablet of 70 mg per week.
Information for Patients Binosto
Professional information leaflet Binosto
Warning for pages closed with password
Please note that the following pages contain information on prescription-only drugs. Under Swiss law, Labatec Pharma is not allowed to make this information accessible to individuals who are not member of the medical or pharmaceutical professions.
Please contact us if you are a client of Labatec interested in getting information and did not yet receive an ID and password.
Click here to continue